Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: QL1706
Drug: Bevacizumab
Drug: Sintilimab
Drug: Oxaliplatin injection
Drug: Capecitabine

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 668

Registration Number: NCT05976568

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Unresectable Gastric Adenocarcinoma

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Drug: Cadonilimab

First Posted Date: 2023-08-03

Last Posted Date: 2023-08-03

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 20

Registration Number: NCT05974059

Locations: 🇨🇳
Xuewei Ding, Tianjin, Tianjin, China

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Phase 2

Recruiting

Conditions: Low Rectal Cancer

Interventions: Radiation: Modified short-course radiotherapy
Drug: PD-1 antibody
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2023-08-02

Last Posted Date: 2024-05-10

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 32

Registration Number: NCT05972655

Locations: 🇨🇳
Sir Run Run Shao hospital, Hanzhou, Zhejiang, China

Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer

Phase 2

Recruiting

Conditions: Colon Neoplasm

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Procedure: Colectomy
Drug: Anti-PD-L1 Monoclonal Antibody
Drug: Clostridium butyricum

First Posted Date: 2023-06-22

Last Posted Date: 2023-08-08

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 100

Registration Number: NCT05914389

Locations: 🇨🇳
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

Phase 1

Recruiting

Conditions: Locally-advanced Rectal Cancer

Interventions: Drug: mFOLFIRINOX
Radiation: Pelvic radiotherapy LCRT
Radiation: Pelvic radiotherapy SCRT
Drug: FOLFOX4
Drug: Capecitabine
Drug: TOLINAPANT (ASTX660)
Drug: CAPOX

First Posted Date: 2023-06-22

Last Posted Date: 2024-02-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 78

Registration Number: NCT05912075

Locations: 🇫🇷
Centre Léon Bérard, Lyon, Rhöne, France
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Phase 2

Recruiting

Conditions: Anal Cancer

Interventions: Radiation: Radiation (reduced elective nodal dose (30.6 Gy)
Drug: Capecitabine
Drug: Mitomycin c

First Posted Date: 2023-06-15

Last Posted Date: 2024-02-23

Lead Sponsor: University of Cincinnati

Target Recruit Count: 33

Registration Number: NCT05902533

Locations: 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Vermont, Burlington, Vermont, United States

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

Not Applicable

Recruiting

Conditions: Locally Advanced
MSS
Rectal Cancer
High-Risk

Interventions: Drug: Toripalimab
Radiation: short-term radiotherapy
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2023-05-26

Last Posted Date: 2023-07-05

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 53

Registration Number: NCT05877573

Locations: 🇨🇳
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Solid Tumor
Non-small Cell Lung Cancer
Gastric Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: RO7496353
Drug: Capecitabine
Drug: Atezolizumab
Drug: Nab-paclitaxel
Drug: S-1
Drug: Gemcitabine
Drug: Nivolumab
Drug: Oxaliplatin

First Posted Date: 2023-05-19

Last Posted Date: 2024-12-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 102

Registration Number: NCT05867121

Locations: 🇺🇸
UCLA University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

and more 26 locations